Mesoblast Names Dr. Gregory George Interim COO to Advance Rexlemestrocel-L Commercialisation

Aakashdeep

10 November 2026 12:56 PM AEDT

Mesoblast Names Dr. Gregory George Interim COO to Advance Rexlemestrocel-L Commercialisation

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Mesoblast Limited (ASX:MSB) has announced an expansion of its operational management structure, appointing Dr. Gregory George as interim Chief Operating Officer while the company undertakes a search for a full-time COO, as it prepares for potential commercial launch activities for its second-generation product rexlemestrocel-L in chronic low back pain and cardiovascular disease.

Key Points

Dr. Gregory George appointed interim COO; he founded and managed SurgCenter Development, described as the largest privately owned ambulatory surgical center company in the United States.
A Phase 3 trial readout for rexlemestrocel-L in inflammatory chronic low back pain is expected during the second half of calendar 2027.
Mesoblast has met with the FDA and obtained alignment on filing a Biologics License Application for rexlemestrocel-L to reduce life-threatening major gastrointestinal bleeding in end-stage heart failure patients supported by a left ventricular assist device.
Chief Medical Officer Dr. Eric Rose will step away from the Board to focus solely on advancing rexlemestrocel-L in the company's cardiopulmonary franchise.

Interim COO Appointment and Commercial Preparations

Mesoblast disclosed that a primary corporate objective is to prepare for commercial manufacturing scale-up and potential commercial launch activities for its rexlemestrocel-L chronic low back pain product. While a search for a permanent Chief Operating Officer is underway, Dr. Gregory George will serve in an interim COO capacity. Dr. George previously founded and managed SurgCenter Development, identified in the filing as the largest privately owned ambulatory surgical center company in the United States. The company stated that Dr. George's immediate focus will be on driving operational efficiencies and accelerating the commercialisation of its cell therapies.

Rexlemestrocel-L Phase 3 and FDA Engagement for Cardiovascular Indication

According to the filing, rexlemestrocel-L has completed Phase 3 programs in both inflammatory chronic low back pain and cardiovascular disease indications. The CLBP Phase 3 trial readout is expected during the second half of calendar 2027. For the cardiovascular indication, Mesoblast disclosed it recently met with the FDA and obtained alignment on filing a Biologics License Application for rexlemestrocel-L targeting the reduction of life-threatening major gastrointestinal bleeding in end-stage heart failure patients kept alive by a left ventricular assist device. The company's stated strategy includes subsequently expanding the label to moderate and severe heart failure and pulmonary hypertension.

Dr. Eric Rose to Step Down from Board, Retain CMO Role

The filing states that Dr. Eric Rose will step away from the Board while continuing in his role as Chief Medical Officer, with his efforts focused on advancing rexlemestrocel-L in the company's cardiopulmonary franchise. The filing notes Dr. Rose as a world-renowned heart surgeon and scientist who performed the world's first successful pediatric heart transplant and, as Chairman of Columbia University's Department of Surgery, contributed to the first FDA approval of an implantable left ventricular assist device for long-term circulatory support. No effective date for Dr. Rose's departure from the Board was specified in the filing.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.